|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of revenues | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Selling and marketing | |||||
| General and administrative | |||||
| Goodwill impairment charge | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Interest expense | |||||
| Financial expense, net | |||||
| Financial income (expense), net | |||||
| Loss before taxes on income | |||||
| Income tax (expense) benefit | |||||
| Net loss | |||||
| Change in foreign currency translation adjustments | |||||
| Total Comprehensive loss | |||||
| Preferred Stock dividends | |||||
| Dividend on Series X Preferred Stock | |||||
| Dividend on Series H Preferred Stock | |||||
| Deemed dividend for down round feature on Series H Preferred Stock | |||||
| Deemed contribution on repurchase of Preferred Series X | |||||
| Deemed contribution on modification of Preferred Series X | |||||
| Net loss available to common stockholders | |||||
| Change in foreign currency translation adjustments | |||||
| Basic net loss available for holders of common stock | |||||
| Diluted net loss available for holders of common stock | |||||
| Weighted average common stock outstanding, basic | |||||
| Weighted average common stock outstanding, diluted | |||||
Loading...